Company announced encouraging translational data supporting pelareorep's mechanism of action across multiple cancer types, demonstrated durable responses in colorectal cancer with 3-4x improvement over historical benchmarks, and achieved FDA alignment on pivotal anal cancer study design. These developments represent meaningful progress in clinical development and regulatory pathway.
Articles that tag ONCY but are mainly about other companies.
Advancing pelareorep oncolytic virus with FDA alignment on pivotal Phase 3 study design for first-line pancreatic cancer. Received Fast Track designation and demonstrated meaningful immune activation in combination studies.
Company presenting new mechanistic data at AACR showing pelareorep triggers immune activation in multiple cancer types; REO 033 trial received FDA Fast Track Designation; consistent evidence accumulating across multiple tumor types with strong efficacy signals (27 months OS, 33% ORR in colorectal cancer vs 10% for standard care).
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
